Inhibitors of sodium-glucose cotransporter 2 (SGLT2is) are an oral hypoglycemic agent, which ameliorates hyperglycemia in type 2 diabetes by promoting urinary glucose excretion via suppression of glucose reabsorption in S1 segment of renal proximal tubule (Yanagisawa et al. 2020). Here, SLC5A2 is linked to type 2 diabetes mellitus.